Abstract
Background: More than 90% of cancer deaths are caused by cancer metastasis. Cancer metastatic therapy is a top priority topic.
Objective: New therapeutics against cancer metastasis is to be discovered.
Methods: In the past pathogenesis study, a therapeutic dilemma has been discovered from literatures of epithelial-mesenchymal cell interchange in late-staged cancer patients—opposite tumor pathogenesis routes between primary and metastatic tumors.
Results: Possible options for overcoming this dilemma are enlisted from different therapeutic attempts (such as novel drug target (cancer biomarkers) discovery, antimetastatic drug developments, biotherapies, drug combinations, cancer therapeutics according to metastatic cascades, different types of personalized medicine paradigms and so on).
Conclusions: These therapeutic options might change the landscape of cancer treatments and managements in clinics forever.
Keywords: Neoplasm metastases, cancer chemotherapy, personalized cancer therapy, drug sensitivity testing, drug combination, pharmacogenetics, personalized medicine.
Current Drug Therapy
Title:Cancer Metastasis, a Clinical Dilemma for Therapeutics
Volume: 11 Issue: 2
Author(s): Da-Yong Lu*, Ting-Ren Lu, Bin Xu, Rong-Xin Qi, Nagendra S. Yarla, Xiao-Die Zhou and Jian Ding
Affiliation:
- Shanghai University, Shanghai 200444, P.R. China.,China
Keywords: Neoplasm metastases, cancer chemotherapy, personalized cancer therapy, drug sensitivity testing, drug combination, pharmacogenetics, personalized medicine.
Abstract: Background: More than 90% of cancer deaths are caused by cancer metastasis. Cancer metastatic therapy is a top priority topic.
Objective: New therapeutics against cancer metastasis is to be discovered.
Methods: In the past pathogenesis study, a therapeutic dilemma has been discovered from literatures of epithelial-mesenchymal cell interchange in late-staged cancer patients—opposite tumor pathogenesis routes between primary and metastatic tumors.
Results: Possible options for overcoming this dilemma are enlisted from different therapeutic attempts (such as novel drug target (cancer biomarkers) discovery, antimetastatic drug developments, biotherapies, drug combinations, cancer therapeutics according to metastatic cascades, different types of personalized medicine paradigms and so on).
Conclusions: These therapeutic options might change the landscape of cancer treatments and managements in clinics forever.
Export Options
About this article
Cite this article as:
Lu Da-Yong*, Lu Ting-Ren, Xu Bin, Qi Rong-Xin, Yarla S. Nagendra, Zhou Xiao-Die and Ding Jian, Cancer Metastasis, a Clinical Dilemma for Therapeutics, Current Drug Therapy 2016; 11 (2) . https://dx.doi.org/10.2174/1574885511666160810143216
DOI https://dx.doi.org/10.2174/1574885511666160810143216 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Recent Advances on the Enantioselective Synthesis of C-Nucleosides Inhibitors of Inosine Monophosphate Dehydrogenase (IMPDH)
Current Topics in Medicinal Chemistry TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued) The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Acute Renal Failure in Different Malignant Tumors
Current Medicinal Chemistry Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs